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Abstract
Coronary artery disease (CAD) is the leading cause of death in both sexes,
accounting for a third of all deaths in developed countries. One of the
mainstays in treatment in both CAD and peripheral arterial disease (PAD)
is the prevention of thrombus formation using antiplatelets, with aspirin
as the drug of choice. Currently, rivaroxaban, a direct factor Xa inhibitor, is
being studied in patients with CAD and PAD. This review addresses the
efficacy of rivaroxaban, with or without aspirin, in the prevention of major
adverse cardiovascular events, in adults with CAD and PAD, compared to
standard of care, aspirin.
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§ CAD and PAD are most commonly the result of atherosclerosis.
§ Many patients with CAD also have PAD. 
§ CAD may present with: asymptomatic ”silent” ischemia; acute coronary 
syndrome (ACS) such as myocardial infarction (MI); sudden cardiac 
death; ischemic stroke.
§ PAD may present as ”silent” ischemia; claudication; pain at rest, skin 
atrophy, hair loss, cyanosis, ulcers, gangrene leading to limb loss.
§ First line treatment for CAD & PAD when not requiring stent/surgery:
Aspirin 75-100 mg once daily
§ It is hypothesized that the selective inhibition of factor Xa could be 
highly effective in preventing the formation of thrombi, as factor Xa is 
positioned at the start of the coagulation pathway.
§ This review analyzes the use of rivaroxaban ± aspirin vs. aspirin alone in 
the prevention of major adverse cardiovascular events (MACEs) and its 
comparative bleeding risks in adults with CAD and PAD.
§ MACEs include cardiovascular death, MI, stroke, and were measured as 
the primary efficacy outcomes in five of the seven studies.
§ Other variables measured were: major adverse limb events (MALE), 
VTE, heart failure, hospitalization, whether or not CABG was needed.
§ Bleeding risk was measured by fatal and non-fatal bleeding events.
Introduction
Methods
§ A literature search was conducted through PubMed and Google 
Scholar in November 2018. 
§ Search terms: “Rivaroxaban” OR “Xarelto” AND “coronary artery 
disease” AND “peripheral vascular disease.” 
§ Seven articles were selected based on relevance to the clinical 
question, publication date after 2013, study design, sample population 
of adults, and outcome measurements. 
All seven studies were found to have adequate blinding,
statistical power, treatment timelines, and follow-up, without
concerns for bias. Outcome measures varied slightly, but all
compared the risk of bleeding vs. benefit of preventing
thrombotic events.
Significant positive results were found in the four studies
using rivaroxaban 2.5 mg BID + aspirin, as well as in the one
study using high dose rivaroxaban in the prevention of VTE.
However, it is important to note that these studies
excluded very high-risk patients, such as those with an
already high bleeding risk, severe heart failure, or end-stage
renal disease.
Discussion Results 
Efficacy of Rivaroxaban (Xarelto) ± Aspirin in the 
Prevention of Major Adverse Cardiovascular Events
The study results are positive:
[Low dose] rivaroxaban 2.5 mg BID  + aspirin 100 mg
once daily offers net clinical benefits in prevention of
MACEs in low- to medium-risk patients with CAD and 
PAD, without significant bleeding risk.
[High dose] rivaroxaban 10mg once a day reduces 
risk of VTE without significant bleeding risk.
These positive outcomes are leading to FDA approval:
• 2017:  10 mg dosing approved to reduce risk of VTE
• 2018:  2.5 mg “vascular dosing” approved to reduce 
risk of major cardiovascular events in patients with 
chronic CAD or PAD
• 2019:  10 mg dosing approved to prevent blood clots 
in acutely ill medical patients.
Major caveat = cost. New oral anticoagulants (NOACs)
such as rivaroxaban are $$$ and can be cost-prohibitive
for patients even with insurance coverage (e.g., high
copay). At this time, overall cost savings and cost-
effectiveness analyses are not available.
Bottom line: Clinicians must choose which medical 
therapy is most appropriate for their patients, both 
medically and financially.
Conclusion
Four studies (Anand et al., Connolly et al., Eikelboom et al., Gibson et al.) showed statistically
significant evidence that rivaroxaban 2.5 mg BID + aspirin 100 mg once daily reduces the risk of
MACEs. These four studies also found that the results of rivaroxaban alone at 5 mg BID were
not statistically significant. One study (Hart et al.) found that rivaroxaban at a high dose of 15
mg once daily was not effective at reducing MACEs but increased the risk of both fatal and non-
fatal bleeding. Another study (Weitz et al.) compared rivaroxaban 10 mg once daily to 20 mg
once daily and found that both reduced VTE without increased bleeding. However, both higher
doses did not reduce MACEs. One study (Mega et al.) did not include aspirin but showed that
rivaroxaban 2.5 mg BID was effective at reducing MACEs. Only one study (Anand et al.) showed
statistically significant evidence that rivaroxaban 2.5 mg reduces the risk of MALEs.
RCT Study Population
Population
Demographic Duration
Treatment Regimen &
Comparator
Primary 
Efficacy 
Outcomes
Clinical 
Benefit 
Bleeding 
Risk
Anand et 
al. (2017)
CAD;
PAD; PAD 
of lower 
extremities
2,109 F
5,361 M
N=7,470
21 
months
1.Rivaroxaban 2.5 mg BID + 
Aspirin 100 mg QD
2.Rivaroxaban 5 mg BID
Comparator: Aspirin 100 mg QD
CV death, 
MI, stroke, 
MALE
1. S
2. NS
1. NS
2. NS
Connolly 
et al. 
(2017)
CAD 5,032 F
19,792 M
N=24,824
23 
months
1.Rivaroxaban 2.5 mg BID + 
Aspirin 100 mg QD
2.Rivaroxaban 5 mg BID
Comparator: Aspirin 100 mg QD
CV death, 
MI, stroke
1. S
2. NS
1. NS
2. NS
Eikelboom 
et al. 
(2017)
CAD;
PAD
6,020 F
21,375 M
N=27,395
23 
months
1.Rivaroxaban 2.5 mg BID + 
Aspirin 100 mg QD
2.Rivaroxaban 5 mg BID
Comparator: Aspirin 100 mg QD
CV death, 
MI, stroke, 
hospitalizati
on
1. S
2. NS
1. NS
2. NS
Gibson et 
al. (2018)
ACS N/A
N=9,435
13.3 
months
1.Rivaroxaban 2.5 mg BID + 
Aspirin 100 mg QD
2.Rivaroxaban 5 mg BID + 
Aspirin 100 mg QD
Comparator: Aspirin 100 mg QD
CV death, 
MI, stroke
1. S
2. S
1. NS
2. NS
Hart et al. 
(2018)
History of 
embolic 
stroke
2,777 F
4,436 M
N=7,213
11 
months
1.Rivaroxaban 15 mg once a 
day;
Comparator: Aspirin 100 mg QD
Recurrent 
stroke, 
systemic 
embolism, 
CV death, 
MI
1. NS 1. S
Mega et 
al. (2012)
ACS 3,936 F
11,600 M
N=15,526
13.1 
months
1.Rivaroxaban 2.5 mg BID + 
Aspirin
2.Rivaroxaban 5 mg BID
Comparator: Placebo
CV death, 
MI, stroke
1. S
2. S
1. NS
2. S
Weitz et 
al. (2017)
VTE 1,531 F
1,865 M
N=3,396
12 
months
1.Rivaroxaban 20 mg once a day
2.Rivaroxaban 10 mg once a day
Comparator: Aspirin 100 mg QD
Recurrent 
VTE
1. S
2. S
1. NS
2. NS
Key: RCT = Randomized Control Trial;  CAD = Coronary Artery Disease; PAD = Peripheral Artery Disease; F = female; 
M = male;  BID = twice a day; QD = once a day; CV = Cardiovascular;  MI = Myocardial Infarction;  MALE = Major 
Adverse Limb Event; ACS = Acute Coronary Syndrome;  N/A = Information Not Available;  VTE = Venous 
Thromboembolism; S = Statistically Significant (P ≤ 0.05); NS = Not Statistically Significant (P ≤ 0.05)
